Author index

Adlercreutz, H. *see* von Hertzen, L.
Agardh, E.E., Carlsson, S., Ahlbom, A., Efendic, S., Grill, V., Hammar, N., Hilding, A. & Östenson, C.-G. Coffee consumption, type 2 diabetes and impaired glucose tolerance in Swedish men and women, 645
Agewall, S. *see* Rohani, M.
Agozzino, F., Picca, M. & Pelosi, G. Association of microalbuminuria and left ventricular hypertrophy, 424
Ahlbom, A. *see* Agardh, E.E.
Ahrén, B. *see* Lindeberg, S.
Airaksinen, K.E.J. *see* Luukinen, H.
Ajello, P. *see* D'Auria, F.
Alessi, M.-C. *see* Mavri, A.
Al-Khalili, F. *see* Janszky, I.
Åman, J. *see* Ingberg, C.-M.
Andersson, S. *see* Wisten, A.
Andersson, U. & Erlandsson-Harris, H. HMGB1 is a potent trigger of arthritis, 344
Andersson, U.G. & Tracey, K.J. HMGB1, a pro-inflammatory cytokine of clinical interest: introduction, 318
Andrès, E. & Dimarcq, J.L. Cationic antimicrobial peptides: update of clinical development, 519
Andrès, E., Noel, E., Schlienger, J.L. & Blicklé, J.F. Mild cobalamin deficiency associated with long-term metformin intake – reply, 302
Arena, V. *see* Incalzi, R.A.
Arner, P. *see* Dahlman, I.
Arnesen, H. *see* Hjerkinn, E.M.
Arnqvist, H. *see* Schölin, A.
Arvidsson, B. *see* Ingberg, C.-M.
Arvidsson, E., Blomqvist, L. & Rydén, M. Depot-specific differences in perilipin mRNA but not protein expression in obesity, 595
Asplund, K. *see* Glader, E.-L.
Asplund, K. *see* Rodu, B.
Axdorph, U. *see* Landgren, O.
Axelsen, M. *see* Johanson, E.H.
Axelsson, C. *see* Svensson, L.
Azaz-Livshits, T. *see* Dormann, H.

Baldissera, E. *see* D'Auria, F.
Barsotti, G. *see* Cupisti, A.
Beevers, D.G. *see* Spencer, C.G.C.
Bek, T. *see* Knudsen, S.T.
Berg, G. *see* Milakovic, M.
Berglund, G. *see* Janzon, E.
Berglund, G. *see* Nilsson, P.M.
Berne, C. *see* Ingberg, C.-M.
Bianchi, M.E. *see* Müller, S.
Bingham, S. *see* Yuyun, M.F.
Bisoendial, R.J. *see* Hovingh, G.K.
Björk, E. *see* Schölin, A.
Björkholm, M. *see* Landgren, O.
Björklund, L. *see* Schölin, A.
Blann, A.D. *see* Spencer, C.G.C.
Bleeker-Rovers, C.P., Jager, G., Tack, C.J., van der Meer, J.W.M. & Oyen, W.J.G. F-18-fluorodeoxyglucose positron emission tomography leading to a diagnosis of septic thrombophlebitis of the portal vein: description of a case history and review of the literature, 419
Blicklé, J.F. *see* Andrès, E.
Blohmé, G. *see* Schölin, A.
Blomqvist, L. *see* Arvidsson, E.
Boissel, J.-P. Planning of clinical trials, 427
Bolinder, J. *see* Schölin, A.
Boonen, S., Haentjens, P., Vandenput, L. & Vanderschueren, D. Preventing osteoporotic fractures with antiresorptive therapy: implications of microarchitectural changes, 1
Borg, H. *see* Schölin, A.
Botta, F. *see* Giannini, E.
Brismar, K. *see* Kistner, A.
Brune, K. *see* Dormann, H.

Cakir, B., Heiss, G., Pankow, J.S., Salomaa, V., Sharrett, A.R., Couper, D. & Weston, B.W. Association of the Lewis genotype with cardiovascular risk factors and subclinical carotid atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) study, 40
Calandra, S. *see* Valdivielso, P.
Capelli, A. *see* Incalzi, R.A.
Carlsson, S. *see* Agardh, E.E.
Carmeliet, P. Manipulating angiogenesis in medicine, 538
Castro Cabezas, M. *see* Halkes, C.J.M.
Celsi, G. *see* Kistner, A.
Chan, M.H.M., Wong, V.W.S., Wong, C.K., Chan, P.K.S., Chu, C.M., Hui, D.S.C., Suen, M.W.M., Sung, J.J.Y., Chung, S.S.C. & Lam, C.W.K. Serum LD1 isoenzyme and blood lymphocyte subsets as prognostic indicators for severe acute respiratory syndrome, 512
Chan, P.K.S. *see* Chan, M.H.M.
Chaves, F.J. *see* Giner, V.
Cheng, T.O. Waist circumference versus body mass index in risk prediction of coronary heart disease: comparing apples and oranges, 690
Chiarbonello, B. *see* Giannini, E.
Chisari, C. *see* Cupisti, A.
Chu, C.M. *see* Chan, M.H.M.
Chung, S.S.C. *see* Chan, M.H.M.
Cole, P. *see* Rodu, B.
Cordain, L. *see* Lindeberg, S.
Cornu, G. *see* Dejardin, A.
Couper, D. *see* Cakir, B.
Criegee-Rieck, M. *see* Dormann, H.
Cupisti, A., Licitra, R., Chisari, C., Stampacchia, G., D'Alessandro, C., Galetta, F., Rossi, B. & Barsotti, G. Skeletal muscle and nutritional assessment in chronic renal failure patients on a protein-restricted diet, 115
Cupisti, A. *see* Franzoni, F.

Dahlman, I., Wahrenberg, H., Persson, L. & Arner, P. No association of reported functional protein tyrosine phosphatase 1B 3′ UTR gene polymorphism with features of the metabolic syndrome in a Swedish population, 694
D'Alessandro, C. *see* Cupisti, A.
van Dam, M. *see* Hovingh, G.K.
D'Auria, F., Rovere-Querini, P., Giazzon, M., Ajello, P., Baldissera, E., Manfredi, A.A. & Sabbadini, M.G. Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-α antibodies, 409
Day, N.E. *see* Yuyun, M.F.
Dejardin, A., Goffette, P., Moulin, P., Verhelst, R., Cornu, G., De Plaen, J.F. & Persu, A. Severe hypoplasia of the abdominal aorta and its branches in a patient and his daughter, 130
Dellborg, M. *see* Gunnarsson, G.
DeMets, D.L. Statistical issues in interpreting clinical trials, 529
De Plaen, J.F. *see* Dejardin, A.
Dimarcq, J.L. *see* Andrès, E.

© 2004 Blackwell Publishing Ltd

Dormann, H., Neubert, A., Criegee-Rieck, M., Egger, T., Radespiel-Tröger, M., Azaz-Livshits, T., Levy, M., Brune, K. & Hahn, E.G. Readmissions and adverse drug reactions in internal medicine: the economic impact, 653
Dotevall, A. *see* Rosengren, A.
Dullaart, R.P.F., Hoogenberg, K., Rouwé, C.W. & Stulp, B.K. Family with autosomal dominant hyperinsulinism associated with A456V mutation in the glucokinase gene, 143
Dunder, K., Lind, L., Zethelius, B. & Lithell, H. A new Q/QS pattern on the resting electrocardiogram is associated with impaired insulin secretion and a poor prognosis in elderly men independently of history of myocardial infarction, 221
Durán, J.C. *see* Valdivielso, P.

Efendic, S. *see* Agardh, E.E.
Egger, T. *see* Dormann, H.
Eggertsen, G. *see* Harper, P.
Eggertsen, R. *see* Milakovic, M.
Engström, G. *see* Janzon, E.
Ericson, M. *see* Janszky, I.
Eriksson, J.W. *see* Schölin, A.
Eriksson, M., Wallander, M.-A., Krakau, I., Wedel, H. & Svärdsudd, K. Birth weight and cardiovascular risk factors in a cohort followed until 80 years of age: the study of men born in 1913, 236
Eriksson, P. *see* Gunnarsson, G.
Erkelens, D.W. *see* Stades, A.M.E.
Erlandsson-Harris, H. *see* Andersson, U.

Felmeden, D.C. *see* Spencer, C.G.C.
Femia, F.R. *see* Franzoni, F.
Ferrer-Barriendos, J. *see* Sambrook, P.N.
Filzmaier, K. *see* Krüger, S.
Floderus, Y. *see* Harper, P.
Forsberg, H. *see* Wisten, A.
Forsblom, C. *see* von Hertzen, L.
Franzoni, F., Galetta, F., Cupisti, A., Femia, F.R., Pentimone, F. & Santoro, G. Ultrasonic backscatter of the carotid wall in young and older athletes, 52
Fumagalli, A. *see* Giannini, E.
Furu, K. *see* Tonstad, S.

Gåfvels, M. *see* Harper, P.
Gaines, K. *see* Sambrook, P.N.
Galetta, F. *see* Cupisti, A.
Galetta, F. *see* Franzoni, F.
Gambassi, G. *see* Incalzi, R.A.
Garuti, R. *see* Valdivielso, P.
Gasbarrini, A. *see* Ojetti, V.
Gasbarrini, G. *see* Ojetti, V.
Gebre-Medhin, M. *see* Milakovic, M.
Geusens, P. *see* Sambrook, P.N.
Giannini, E., Risso, D., Botta, F., Romagnoli, P., Malfatti, F., Fumagalli, A., Testa, E., Podestà, E., Chiarbonello, B., Polegato, S. & Testa, R. Prognosis of hepatocellular carcinoma in anti-HCV positive cirrhotic patients: a single-centre comparison amongst four different staging systems, 399
Giazzon, M. *see* D'Auria, F.
Giner, V., Tormos, C., Chaves, F.J., Sáez, G. & Redón, J. Microalbuminuria and oxidative stress in essential hypertension, 588
Glader, E.-L., Stegmayr, B., Norrving, B., Terént, A., Hulter-Åsberg, K., Wester, P.-O. & Asplund, K. for the Riks-Stroke Collaboration. Large variations in the use of oral anticoagulants in stroke patients with atrial fibrillation: a Swedish national perspective, 22
Gleim, G.W. & Tressler, C.S. Effects of losartan on diabetic maculopathy in type 2 diabetic patients, 304
Goffette, P. *see* Dejardin, A.
González, P. *see* Valdivielso, P.
Graf, J. *see* Krüger, S.
Grill, V. *see* Agardh, E.E.
Grimfors, G. *see* Landgren, O.
Groen, A.K. *see* Hovingh, G.K.
Grønbæk, M. *see* Nielsen, N.R.
Groop, P.-H. *see* von Hertzen, L.
Grove, E.L., Ørntoft, T.F., Lassen, J.F., Jensen, H.K. & Kristensen, S.D. The platelet polymorphism PlA^{2} is a genetic risk factor for myocardial infarction, 637
Gudbjörnsdottir, S. *see* Schölin, A.
Gunnarsson, G., Eriksson, P. & Dellborg, M. Continuous ST-segment monitoring of patients with left bundle branch block and suspicion of acute myocardial infarction, 571
Gurney, D. *see* Spencer, C.G.C.
Gustafson, B. *see* Johanson, E.H.
Gustavsson, A. *see* Landgren, O.

Haentjens, P. *see* Boonen, S.
Hahn, E.G. *see* Dormann, H.
Halkes, C.J.M., van Wijk, J.P.H., Ribalta, J., Masana, L. & Castro Cabezas, M. Diurnal triglyceridaemia and insulin resistance in mildly obese subjects with normal fasting plasma lipids, 74
Hallert, C. *see* Löfgren, U.-B.
Hammar, N. *see* Agardh, E.E.
Hanrath, P. *see* Krüger, S.
Hansson, L.-O. *see* Saleh, N.
Harper, P., Floderus, Y., Holmström, P., Eggertsen, G. & Gåfvels, M. Enrichment of *HFE* mutations in Swedish patients with familial and sporadic form of porphyria cutanea tarda, 684
Hasselblom, S., Linde, A. & Ridell, B. Hodgkin's lymphoma, Epstein–Barr virus reactivation and fatal haemophagocytic syndrome, 289
Hauser, A.C., Lorenz, M. & Sunder-Plassmann, G. The expanding clinical spectrum of Anderson–Fabry disease: a challenge to diagnosis in the novel era of enzyme replacement therapy, 629
Hayden, M.R. *see* Hovingh, G.K.
Hedblad, B. *see* Janzon, E.
Heickendorff, L. *see* Kanstrup, H.
Heikens, J.T. *see* Stades, A.M.E.
Heiss, G. *see* Cakir, B.
Herlitz, J. *see* Svensson, L.
Herrera, E. *see* Valdivielso, P.
von Hertzen, L., Forsblom, C., Stumpf, K., Pettersson-Fernholm, K., Adlercreutz, H. & Groop, P.-H. on behalf of the finndiane study group. Highly elevated serum phyto-oestrogen concentrations in patients with diabetic nephropathy, 602
Hilding, A. *see* Agardh, E.E.
Hjerkinn, E.M., Sandvik, L., Hjermann, I. & Arnesen, H. Effect of diet intervention on long-term mortality in healthy middle-aged men with combined hyperlipidaemia, 68
Hjermann, I. *see* Hjerkinn, E.M.
Hoekstra, J.B.L. *see* Stades, A.M.E.
Hoffmann, R. *see* Krüger, S.
Holleman, F. *see* Stades, A.M.E.
Holmström, P. *see* Harper, P.
Hölzl, B. *see* Strohmer, B.
Hoogenberg, K. *see* Dullaart, R.P.F.
Hove, M.N. *see* Knudsen, S.T.
Hovingh, G.K., Kuivenhoven, J.A., Bisoendial, R.J., Groen, A.K., van Dam, M., van Tol, A., Wellington, C., Hayden, M.R., Smelt, A.H.M. & Kastelein, J.J.P. HDL deficiency and atherosclerosis: lessons from Tangier disease, 299
Hui, D.S.C. *see* Chan, M.H.M.
Hulter-Åsberg, K. *see* Glader, E.-L.
Hutri-Kähönen, N. *see* Juonala, M.

Huttunen, H.J. & Rauvala, H. Amphoterin as an extracellular regulator of cell motility: from discovery to disease, 351

Incalzi, R.A., Arena, V., Capelli, A. & Gambassi, G. Isolated PACNS-like presentation of a systemic vasculitis complicating a myelodysplastic syndrome, 674
Ingberg, C.-M., Palmér, M., Åman, J., Arvidsson, B., Schvarcz, E. & Berne, C. Body composition and bone mineral density in long-standing type 1 diabetes, 392
Izhevsky, D., Maple, J.T. & Ommen, S.R. Acute myocardial infarction: an unusual culmination of rheumatic pancarditis and antiphospholipid antibody syndrome, 296

Jacobson, S.H. *see* Kistner, A.
Jager, G. *see* Bleeker-Rovers, C.P.
Janssens, U. *see* Krüger, S.
Jansson, P.-A. *see* Johanson, E.H.
Janszky, I., Ericson, M., Mittleman, M.A., Wamala, S., Al-Khalili, F., Schenck-Gustafsson, K. & Orth-Gomer, K. Heart rate variability in long-term risk assessment in middle-aged women with coronary heart disease: The Stockholm Female Coronary Risk Study, 13
Janzon, E., Hedblad, B., Berglund, G. & Engström, G. Changes in blood pressure and body weight following smoking cessation in women, 266
Jensen, G. *see* Nielsen, N.R.
Jensen, H.K. *see* Grove, E.L.
Johanson, E.H., Jansson, P.-A., Gustafson, B., Lönn, L., Smith, U., Taskinen, M.-R. & Axelsen, M. Early alterations in the postprandial VLDL1 apoB-100 and apoB-48 metabolism in men with strong heredity for type 2 diabetes, 273
Johansson, S. *see* Rosengren, A.
Jokinen, E. *see* Juonala, M.
Jönsson, B. *see* Lindgren, P.
Juhan-Vague, I. *see* Mavri, A.
Julian, D.G. Translation of clinical trials into clinical practice, 309
Jungner, I. *see* Walldius, G.
Juonala, M., Viikari, J.S.A., Hutri-Kähönen, N., Pietikäinen, M., Jokinen, E., Taittonen, L., Marniemi, J., Rönnemaa, T. & Raitakari, O.T. The 21-year follow-up of the Cardiovascular Risk in Young Finns Study: risk factor levels, secular trends and east–west difference, 457

Kalin, M. *see* Landgren, O.
Kanstrup, H., Lassen, J.F., Heickendorff, L., Lauritzen, T. & Larsen, M.L. Quality of lipid-lowering therapy in patients with ischaemic heart disease: a register-based study in 3477 patients, 367
Karlsson, A.F. *see* Schölin, A.
Kastelein, J.J.P. *see* Hovingh, G.K.
Kawabe, J. *see* Takehara, N.
Kawamura, Y. *see* Takehara, N.
Khaw, K.-T. *see* Yuyun, M.F.
Kikuchi, K. *see* Takehara, N.
Kistner, A., Jacobson, S.H., Celsi, G., Vanpee, M. & Brismar, K. IGFBP-1 levels in adult women born small for gestational age suggest insulin resistance in spite of normal BMI, 82
Kitabatake, A. *see* Takehara, N.
Knudsen, S.T., Bek, T., Poulsen, P.L., Hove, M.N., Rehling, M. & Mogensen, C.E. Effects of losartan on diabetic maculopathy in type 2 diabetic patients – reply, 306
Kobayashi, J. *see* Yagi, K.
Konradsen, H.B. *see* Landgren, O.
Konstantopoulou, P. *see* Vemmos, K.N.
Koski, K. *see* Luukinen, H.
Krakau, I. *see* Eriksson, M.
Krantz, P. *see* Wisten, A.
Kristensen, S.D. *see* Grove, E.L.
Krüger, S., Filzmaier, K., Graf, J., Kunz, D., Stickel, T., Hoffmann, R., Hanrath, P. & Janssens, U. QRS prolongation on surface ECG and brain natriuretic peptide as indicators of left ventricular systolic dysfunction, 206
Kuivenhoven, J.A. *see* Hovingh, G.K.
Kunz, D. *see* Krüger, S.

Labouriau, R. *see* Niemann, T.
Laippala, P. *see* Luukinen, H.
Lam, C.W.K. *see* Chan, M.H.M.
Landgren, O., Björkholm, M., Konradsen, H.B., Söderqvist, M., Nilsson, B., Gustavsson, A., Axdorph, U., Kalin, M. & Grimfors, G. A prospective study on antibody response to repeated vaccinations with pneumococcal capsular polysaccharide in splenectomized individuals with special reference to Hodgkin's lymphoma, 664
Larsen, M.L. *see* Kanstrup, H.
Lassen, J.F. *see* Grove, E.L.
Lassen, J.F. *see* Kanstrup, H.
Lauritzen, T. *see* Kanstrup, H.
Lazar, M.A. *see* Steppan, C.M.
Levy, M. *see* Dormann, H.
Licitra, R. *see* Cupisti, A.
Lind, L. *see* Dunder, K.
Lind, L. *see* Olsson, T.
Linde, A. *see* Hasselblom, S.
Lindeberg, S., Cordain, L., Råstam, L. & Ahrén, B. Serum uric acid in traditional Pacific Islanders and in Swedes, 373
Lindgren, P., Jönsson, B. & Yusuf, S. Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the cure trial, 562
Lindstedt, G. *see* Milakovic, M.
Lindström, T. *see* Löfgren, U.-B.
Lip, G.Y.H. *see* Spencer, C.G.C.
Lithell, H. *see* Dunder, K.
Löfgren, U.-B., Rosenqvist, U., Lindström, T., Hallert, C. & Nystrom, F.H. Diabetes control in Swedish community dwelling elderly: more often tight than poor, 96
Lönn, L. *see* Johanson, E.H.
Lorenz, M. *see* Hauser, A.C.
Luben, R. *see* Yuyun, M.F.
Luukinen, H., Koski, K., Laippala, P. & Airaksinen, K.E.J. Orthostatic hypotension and the risk of myocardial infarction in the home-dwelling elderly, 486

Mabuchi, H. *see* Yagi, K.
Machin, D. On the evolution of statistical methods as applied to clinical trials, 521
Makita, N. *see* Takehara, N.
Malfatti, F. *see* Giannini, E.
Manfredi, A.A. *see* D'Auria, F.
Manios, E. *see* Vemmos, K.N.
Maple, J.T. *see* Izhevsky, D.
Marniemi, J. *see* Juonala, M.
Masana, L. *see* Halkes, C.J.M.
Mathai, D. *see* Varghese, G.M.
Mavri, A., Alessi, M.-C. & Juhan-Vague, I. Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseases, 448
Mavrikakis, M. *see* Vemmos, K.N.
van der Meer, J.W.M. *see* Bleeker-Rovers, C.P.
Melton, M.E. *see* Sambrook, P.N.
Merlini, G. & Westermark, P. The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies, 159
Messner, T. *see* Wisten, A.
Migneco, A. *see* Ojetti, V.

Milakovic, M., Berg, G., Nyström, E., Lindstedt, G., Gebre-Medhin, M. & Eggertsen, R. Urinary iodine and thyroid volume in a Swedish population, 610
Mittleman, M.A. *see* Janszky, I.
Mogensen, C.E. *see* Knudsen, S.T.
Mosekilde, L. *see* Vestergaard, P.
Moulin, P. *see* Dejardin, A.
Müller, S., Ronfani, L. & Bianchi, M.E. Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function, 332

Nasic, S. *see* Rodu, B.
Neubert, A. *see* Dormann, H.
Nielsen, N.R., Schnohr, P., Jensen, G. & Grønbæk, M. Is the relationship between type of alcohol and mortality influenced by socio-economic status?, 280
Niemann, T., Labouriau, R., Sørensen, H.T., Thorsgaard, N. & Nielsen, T.T. Prognostic impact of different regional referral practices for interventional investigation and coronary treatment after exercise testing: a population-based 5-year follow-up study, 478
Nilsson, B. *see* Landgren, O.
Nilsson, J.-Å. *see* Nilsson, P.M.
Nilsson, P.M., Nilsson, J.-Å. & Berglund, G. Family burden of cardiovascular mortality: risk implications for offspring in a national register linkage study based upon the Malmö Preventive Project, 229
Nilsson, T. *see* Saleh, N.
Nista, E.C. *see* Ojetti, V.
Noel, E. *see* Andrès, E.
Nordlander, R. *see* Svensson, L.
Norrving, B. *see* Glader, E.-L.
Nyström, E. *see* Milakovic, M.
Nystrom, F.H. *see* Löfgren, U.-B.
Nyström, L. *see* Schölin, A.

Ojetti, V., Migneco, A., Zocco, M.A., Nista, E.C., Gasbarrini, G. & Gasbarrini, A. Beta-lactamase inhibitor enhances *Helicobacter pylori* eradication rate, 125
Olsson, T., Terent, A. & Lind, L. Rapid Emergency Medicine score: a new prognostic tool for in-hospital mortality in nonsurgical emergency department patients, 579
Ommen, S.R. *see* Izhevsky, D.
Ørntoft, T.F. *see* Grove, E.L.
Orth-Gomer, K. *see* Janszky, I.
Östenson, C.-G. *see* Agardh, E.E.
Östman, J. *see* Schölin, A.
Oyen, W.J.G. *see* Bleeker-Rovers, C.P.

Palmér, M. *see* Ingberg, C.-M.
Pankow, J.S. *see* Cakir, B.
Paulweber, B. *see* Strohmer, B.
Pedrinelli, R. Association of microalbuminuria and left ventricular hypertrophy – reply, 426
Pelosi, G. *see* Agozzino, F.
Pentimone, F. *see* Franzoni, F.
Persson, L. *see* Dahlman, I.
Persu, A. *see* Dejardin, A.
Peter, S. *see* Varghese, G.M.
Pettersson-Fernholm, K. *see* von Hertzen, L.
Picca, M. *see* Agozzino, F.
Pietikäinen, M. *see* Juonala, M.
Podestà, E. *see* Giannini, E.
Polegato, S. *see* Giannini, E.
Poulsen, P.L. *see* Knudsen, S.T.

Radespiel-Tröger, M. *see* Dormann, H.
Raitakari, O.T. *see* Juonala, M.
Råstam, L. *see* Lindeberg, S.
Rauvala, H. *see* Huttunen, H.J.
Redón, J. *see* Giner, V.
Reginster, J.-Y. Prevention of postmenopausal osteoporosis with pharmacological therapy: practice and possibilities, 615
Rehling, M. *see* Knudsen, S.T.
Reiter, R. *see* Strohmer, B.
Ribalta, J. *see* Halkes, C.J.M.
Ribot, C. *see* Sambrook, P.N.
Ridell, B. *see* Hasselblom, S.
Risso, D. *see* Giannini, E.
Rodu, B., Stegmayr, B., Nasic, S., Cole, P. & Asplund, K. The influence of smoking and smokeless tobacco use on weight amongst men, 102
Rohani, M. & Agewall, S. Oral snuff impairs endothelial function in healthy snuff users, 379
Romagnoli, P. *see* Giannini, E.
Ronfani, L. *see* Müller, S.
Rönnemaa, T. *see* Juonala, M.
Rosengren, A., Dotevall, A., Wilhelmsen, L., Thelle, D. & Johansson, S. Coffee and incidence of diabetes in Swedish women: a prospective 18-year follow-up study, 89
Rosenqvist, U. *see* Löfgren, U.-B.
Rossi, B. *see* Cupisti, A.
Rosvold, E.O. *see* Tonstad, S.
Rouwé, C.W. *see* Dullaart, R.P.F.
Rovere-Querini, P. *see* D'Auria, F.
Rydén, M. *see* Arvidsson, E.

Sabbadini, M.G. *see* D'Auria, F.
Sáez, G. *see* Giner, V.
Saleh, N., Svane, B., Velander, M., Nilsson, T., Hansson, L.-O. & Tornvall, P. C-reactive protein and myocardial infarction during percutaneous coronary intervention, 33
Salomaa, V. *see* Cakir, B.
Sambrook, P.N., Geusens, P., Ribot, C., Solimano, J.A., Ferrer-Barriendos, J., Gaines, K., Verbruggen, N. & Melton, M.E. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (*EF*ficacy of *F*OSAMAX® versus *E*VISTA® *C*omparison *T*rial) International, 503
Sandvik, L. *see* Hjerkinn, E.M.
Santoro, G. *see* Franzoni, F.
Sato, N. *see* Takehara, N.
Schenck-Gustafsson, K. *see* Janszky, I.
Schlienger, J.L. *see* Andrès, E.
Schnohr, P. *see* Nielsen, N.R.
Schölin, A., Björklund, L., Borg, H., Arnqvist, H., Björk, E., Blohmé, G., Bolinder, J., Eriksson, J.W., Gudbjörnsdottir, S., Nyström, L., Östman, J., Karlsson, A.F. & Sundkvist, G. Islet antibodies and remaining β-cell function 8 years after diagnosis of diabetes in young adults: a prospective follow-up of the nationwide Diabetes Incidence Study in Sweden, 384
Schvarcz, E. *see* Ingberg, C.-M.
Sharrett, A.R. *see* Cakir, B.
Shenoy, M. *see* Varghese, G.M.
Shiobara, S. *see* Yagi, K.
Skurtveit, S. *see* Tonstad, S.
Sleight, P. Where are clinical trials going? Society and clinical trials, 151
Smelt, A.H.M. *see* Hovingh, G.K.
Smith, U. *see* Johanson, E.H.
Söderqvist, M. *see* Landgren, O.
Solimano, J.A. *see* Sambrook, P.N.

Sørensen, H.T. *see* Niemann, T.
Spencer, C.G.C., Gurney, D., Felmeden, D.C., Blann, A.D., Beevers, D.G. & Lip, G.Y.H. Platelet and haemorheological markers in 'high risk' hypertensives are improved by tighter blood pressure control and cardiovascular risk management: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), 59
Spengos, K. *see* Vemmos, K.N.
Stades, A.M.E., Heikens, J.T., Erkelens, D.W., Holleman, F. & Hoekstra, J.B.L. Metformin and lactic acidosis: cause or coincidence? A review of case reports, 179
Stampacchia, G. *see* Cupisti, A.
Stegmayr, B. *see* Glader, E.-L.
Stegmayr, B. *see* Rodu, B.
Steppan, C.M. & Lazar, M.A. The current biology of resistin, 439
Stickel, T. *see* Krüger, S.
Strohmer, B., Reiter, R., Hölzl, B. & Paulweber, B. Lack of association of the Gly972Arg mutation of the insulin receptor substrate-1 gene with coronary artery disease in the Austrian population, 146
Stulp, B.K. *see* Dullaart, R.P.F.
Stumpf, K. *see* von Hertzen, L.
Subramanian, S. *see* Varghese, G.M.
Suen, M.W.M. *see* Chan, M.H.M.
Sunder-Plassmann, G. *see* Hauser, A.C.
Sundkvist, G. *see* Schölin, A.
Sung, J.J.Y. *see* Chan, M.H.M.
Svane, B. *see* Saleh, N.
Svärdsudd, K. *see* Eriksson, M.
Svensson, L., Axelsson, C., Nordlander, R. & Herlitz, J. Prognostic value of biochemical markers, 12-lead ECG and patient characteristics amongst patients calling for an ambulance due to a suspected acute coronary syndrome, 469
Synetos, A. *see* Vemmos, K.N.

Tack, C.J. *see* Bleeker-Rovers, C.P.
Taittonen, L. *see* Juonala, M.
Takehara, N., Makita, N., Kawabe, J., Sato, N., Kawamura, Y., Kitabatake, A. & Kikuchi, K. A cardiac sodium channel mutation identified in Brugada syndrome associated with atrial standstill, 137
Taskinen, M.-R. *see* Johanson, E.H.
Terént, A. *see* Glader, E.-L.
Terent, A. *see* Olsson, T.
Testa, E. *see* Giannini, E.
Testa, R. *see* Giannini, E.
Thelle, D. *see* Rosengren, A.
Thorsgaard, N. *see* Niemann, T.
Toftegaard Nielsen, T. *see* Niemann, T.
van Tol, A. *see* Hovingh, G.K.
Tonstad, S., Rosvold, E.O., Furu, K. & Skurtveit, S. Undertreatment and overtreatment with statins: the Oslo Health Study 2000–2001, 494
Tormos, C. *see* Giner, V.
Tornvall, P. *see* Saleh, N.
Tracey, K.J. *see* Andersson, U.G.
Tracey, K.J. *see* Wang, H.
Tressler, C.S. *see* Gleim, G.W.
Tsivgoulis, G. *see* Vemmos, K.N.

Valdivielso, P., Calandra, S., Durán, J.C., Garuti, R., Herrera, E. & González, P. Coronary heart disease in a patient with cerebrotendinous xanthomatosis, 680
Vandenput, L. *see* Boonen, S.
Vanderschueren, D. *see* Boonen, S.
Vanpee, M. *see* Kistner, A.
Varghese, G.M., Shenoy, M., Subramanian, S., Peter, S. & Mathai, D. Colonic malignancy with recurrent bacteraemia presenting as pyrexia of unknown origin, 692
Velander, M. *see* Saleh, N.
Vemmos, K.N., Tsivgoulis, G., Spengos, K., Zakopoulos, N., Synetos, A., Manios, E., Konstantopoulou, P. & Mavrikakis, M. U-shaped relationship between mortality and admission blood pressure in patients with acute stroke, 257
Verbruggen, N. *see* Sambrook, P.N.
Verhelst, R. *see* Dejardin, A.
Vestergaard, P. & Mosekilde, L. Parathyroid surgery is associated with a decreased risk of hip and upper arm fractures in primary hyperparathyroidism: a controlled cohort study, 108
Viikari, J.S.A. *see* Juonala, M.

Wahrenberg, H. *see* Dahlman, I.
Wallander, M.-A. *see* Eriksson, M.
Walldius, G. & Jungner, I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy, 188
Wamala, S. *see* Janszky, I.
Wang, H., Yang, H. & Tracey, K.J. Extracellular role of HMGB1 in inflammation and sepsis, 320
Wareham, N.J. *see* Yuyun, M.F.
Wedel, H. *see* Eriksson, M.
Welch, A. *see* Yuyun, M.F.
Wellington, C. *see* Hovingh, G.K.
Wester, P.-O. *see* Glader, E.-L.
Westermark, P. *see* Merlini, G.
Weston, B.W. *see* Cakir, B.
van Wijk, J.P.H. *see* Halkes, C.J.M.
Wilhelmsen, L. *see* Rosengren, A.
Wisten, A., Andersson, S., Forsberg, H., Krantz, P. & Messner, T. Sudden cardiac death in the young in Sweden: electrocardiogram in relation to forensic diagnosis, 213
Wong, C.K. *see* Chan, M.H.M.
Wong, V.W.S. *see* Chan, M.H.M.

Yagi, K., Kobayashi, J., Yasue, S., Yamaguchi, M., Shiobara, S. & Mabuchi, H. Four unrelated cases with Takayasu arteritis and CD36 deficiency: possible link between these disorders, 688
Yamaguchi, M. *see* Yagi, K.
Yang, H. *see* Wang, H.
Yasue, S. *see* Yagi, K.
Yusuf, S. *see* Lindgren, P.
Yuyun, M.F., Khaw, K.-T., Luben, R., Welch, A., Bingham, S., Day, N.E. & Wareham, N.J. Microalbuminuria and stroke in a British population: the European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study, 247

Zakopoulos, N. *see* Vemmos, K.N.
Zethelius, B. *see* Dunder, K.
Zocco, M.A. *see* Ojetti, V.

Keyword index

α(1,3/1,4)-L-fucosyltransferase, 40
acute myocardial infarction, 571
acute stroke, 257
adipokines, 439
adipose, 439
adipose tissue, 448, 595
adverse drug reaction, 653
age, 266
ageing, 52, 486
albuminuria, 247
alcoholic beverages, 280
alendronate, 503
amoxicillin–clavulanate, 125
amyloid, 159
amyloidosis, 159
Anderson–Fabry disease, 629
angiogenesis, 538
antibody response, 664
antioxidants, 588
antiphospholipid syndrome, 296
aortic hypoplasia, 130
apolipoproteins, 188
apoproteins, 273
apoptosis, 409
arteriogenesis, 538
arthritis, 320, 344
atherosclerosis, 52, 74, 188, 680
atrial fibrillation, 22
atrial standstill, 137
autoimmunity, 409, 674

β-lactamase inhibitor, 125
Bayesian methods, 521
BCLC staging system, 399
biguanides, 179
biochemical markers, 469
birth weight, 236
bisphosphonates, 503
blood glucose, 96
blood pressure, 236, 257, 266, 486
body composition, 392
bone density, 1
bone microarchitecture, 1
bone mineral density, 392
brachial artery, 379
brain natriuretic peptide, 206
Brugada syndrome, 137

cardiac variant, 629
cardiovascular, 229, 457
cardiovascular disease, 13, 247, 448, 494, 562
cardiovascular risk, 188
carditis, 296
carotid atherosclerosis, 40
carrier females, 629
case series, 179
cell migration, 351
cerebrotendinous xanthomatosis, 680
cerebrovascular accident, 247
cholestanol, 680
cholesterol, 236, 367, 680
chromatin, 332
chronic heart failure, 206
chronic renal failure, 115
clinical history, 469
clinical trial, 309, 427
CLIP score, 399
clopidogrel, 562
coarctation, 130
coffee, 89, 645
cohort, 108, 579
compliance, 96
conflict of interest, 151
confounding factors, 280
coronary angiography, 478
coronary heart disease, 680
coronary syndrome, 469
cost-effectiveness, 562
Cox model, 521
C-peptide, 384
C-reactive protein, 33
cross-sectional studies, 645
cytokine, 318, 344

daidzein, 602
data and safety monitoring, 151
decision models, 562
development, 332
diabetes, 89, 96, 236, 384
diabetes mellitus, 439
diabetes mellitus type 2, 179
diagnosis, 571
diet, 68, 373
DNA damage, 588
doctor's practice patterns, 478
dual energy X-ray absorptiometry (DEXA), 392

ECG, 469
echocardiography, 206
economics, 562
elderly, 96
electrocardiogram, 213, 221
electrocardiography, 206
embolism, 22
emergency department, 579
endothelial cell, 538
endothelial function, 379
enterolactone, 602
epidemiology, 373, 579, 645
exercise test, 478

F-18-fluorodeoxyglucose, 419
Fabry disease, 629
family history, 229, 494
fat mass, 392
fetal growth retardation, 82
fever, 674
fever of unknown origin (FUO), 419
fibrates, 188
fibril protein, 159
fibrinogen, 59
fibrinolysis, 448
fibromuscular dysplasia, 130
flow-mediated dilatation, 379
forensic diagnosis, 213
fracture, 108
fracture reduction, 1
fraud, 151
FUT3 gene, 40

GADA, 384
genistein, 602
glucose intolerance, 645
goitre, 610
GRETCH model, 399
guidelines, 309, 494

health economics, 151
heart rate variability, 13
heparin sulphates, 351
hepatitis C virus, 399
hepatocelluar carcinoma, 399
higher *H. pylori* eradication rate, 125
hip fracture, 108
HMG, 351
HMGB, 332
HMGB1, 318, 320, 344
Hodgkin's disease, 289
Hodgkin's lymphoma, 664
hospital readmission, 653
human herpesvirus 4, 289
humans, 373
hyperlipidaemia, 68
hypertension, 59, 236, 588
hypertrigly-ceridaemia, 68
hypotension, 486

IA-2A, 384
ICA, 384
IGF-I and IGFBP-1 levels, 82
inflammation, 318, 320, 332, 448, 674
infliximab, 409
information technology, 653
insulin, 82, 96, 645
insulin resistance, 74, 273, 373, 439
insulin resistance syndrome, 448
insulin secretion, 221
intent to treat, 529
intima–media thickness, 52
intracerebral haemorrhage, 257
ischaemic heart disease, 367
ischaemic stroke, 257

ketoacids low protein diet, 115

lactate dehydrogenase isoenzyme, 512
lactic acidosis, 179
left bundle branch block, 571
left ventricular systolic dysfunction, 206
Lewis gene, 40
lipid-lowering therapy, 367
logrank, 521
longitudinal, 266
lymphocyte subsets, 512

maternal, 229
metabolic syndrome, 74
metastasis, 332
metformin, 179

© 2004 Blackwell Publishing Ltd

methodology, 427
microalbuminuria, 588
Minnesota code, 213
mortality, 13, 68, 229, 257, 280
mortality prediction, 579
mRNA, 595
multiple ROC analysis, 512
myelodysplastic syndrome, 674
myocardial infarction, 33, 221, 296, 486, 637
myocardial revascularization, 478

necrosis, 318, 344
nephropathy, 602
neurite outgrowth, 351
nicotine, 379
nicotinic acid, 188
non-Langerhans-cell histiocytosis, 289
nucleosomes, 409
nutritional status, 115

obesity, 74, 439
Okuda staging system, 399
omental, 595
omeprazole, 125
oral anti-coagulants, 22
orthostatic hypotension, 486
osteoporosis, 1, 615
overweight, 102
oxidative stress, 588

PAI-1, 448
Papua New Guinea, 373
pathogenesis, 344
pathophysiology, 512
percutaneous coronary intervention, 33
perilipin, 595
pharmacology, 615
pharmaco-vigilance, 653
physical exercise, 52
phyto-oestrogens, 602
plasma viscosity, 59
platelet aggregation, 637
platelet glycoprotein GP IIb/IIIa complex, 637
platelets, 637
pneumococcal, 664
polymorphism, 637
poor prognosis, 221
population, 89, 610
positron emission tomography, 419
postmenopausal, 615
postmenopausal osteoporosis, 503
post-prandial, 273
postprandial lipaemia, 74
prehospital, 469
preterm birth, 82
prevention, 22, 494, 615
primary hyperparathyroidism, 108
Procainamide, 137
procedure time, 33
prognosis, 13, 469, 512
prospective study, 280
protein, 595
proteinuria, 247
pylephlebitis, 419

Q/QS pattern, 221
QRS complex, 206
quality of care, 653

RAGE, 351
RAGE ligand, 318
raloxifene, 503
randomization, 521
randomization bias, 151
randomized, 309
registers, 367
renal variant, 629
resistin, 439
resource utilization, 653
revaccination, 664
rheological indices, 59
rheumatic fever, 296
rheumatoid arthritis, 409
risk factors, 68, 179, 229, 247, 457, 588, 615, 637

S100, 351
sample size, 521
SCN5A, 137
scoring system, 579
secular trend, 457
selective oestrogen receptor modulators, 503
sepsis, 318, 320
septic thrombophlebitis, 419
serum lipids, 82
severe acute respiratory syndrome (SARS), 512
shock, 320
side effects, 125
skeletal muscle, 115
skinfold thickness, 392
smokeless tobacco, 102
smoking, 68, 102
smoking cessation, 102, 266
snuff, 379
snus, 102
social class, 229, 280
soluble P-selectin, 59
splenectomy, 664
statins, 188, 367, 494
stem cells, 538
stent implantation, 33
Sterol 27-hydroxylase, 680
stroke, 22
ST-segment monitoring, 571
subcutaneous, 595
subgroups, 529
sudden cardiac death, 213
surgery, 108
surrogate outcomes, 529
surveys, 309
Sweden, 213, 562
symptoms, 629
systemic amyloidosis, 159
systemic lupus erythematosus, 409

therapy, 344
thyroid volume, 610
TNF, 320
treatment, 96
treatment outcome, 478
trial ethics, 151
triglyceride-rich lipoproteins, 273
triglycerides, 74, 236
triple therapy, 125
troponin T, 33
type 1 diabetes, 602
type 1 diabetes mellitus, 392
type 2 diabetes mellitus, 645

ultrasonics, 52
ultrasonography, 610
ultrasound, 379
uric acid, 373
urinary iodine, 610

vaccination, 664
vascular endothelial growth factor, 538
vasculitis, 674
vasculogenesis, 538
vectorcardiography, 571
ventricular fibrillation, 137
viral DNA, 289

weight gain, 266
von Willebrand factor, 59
women, 13, 82, 89, 266
women's health, 615

young, 213
young adults, 384